A Quarter Of Chinese At Risk Of CVD, With 2006-2015 Costs Estimated At $558 Billion
This article was originally published in PharmAsia News
At a recent World Congress of Cardiology gathering in Beijing, leading experts underscored the severity of China's cardiovascular disease (CVD) situation, and promoted the preventative use of aspirin to control risk factors
You may also be interested in...
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.
Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.